Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5171168
Max Phase: Preclinical
Molecular Formula: C19H24ClN5O2S
Molecular Weight: 421.95
Associated Items:
ID: ALA5171168
Max Phase: Preclinical
Molecular Formula: C19H24ClN5O2S
Molecular Weight: 421.95
Associated Items:
Canonical SMILES: CC(=O)Nc1ncc(CN2CCN(CC(=O)Nc3ccc(Cl)cc3)CC2C)s1
Standard InChI: InChI=1S/C19H24ClN5O2S/c1-13-10-24(12-18(27)23-16-5-3-15(20)4-6-16)7-8-25(13)11-17-9-21-19(28-17)22-14(2)26/h3-6,9,13H,7-8,10-12H2,1-2H3,(H,23,27)(H,21,22,26)
Standard InChI Key: IILJNGRUWDDWLI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 421.95 | Molecular Weight (Monoisotopic): 421.1339 | AlogP: 2.90 | #Rotatable Bonds: 6 |
Polar Surface Area: 77.57 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.01 | CX Basic pKa: 5.85 | CX LogP: 2.41 | CX LogD: 2.30 |
Aromatic Rings: 2 | Heavy Atoms: 28 | QED Weighted: 0.75 | Np Likeness Score: -2.35 |
1. Li X, Han J, Bujaranipalli S, He J, Kim EY, Kim H, Im JH, Cho WJ.. (2022) Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease., 238 [PMID:35588599] [10.1016/j.ejmech.2022.114444] |
Source(1):